Anjiyogenezin temel moleküler mekanizmaları ve tümör anjiyogenezi

Anjiogenez, mevcut kan damarlarından yeni kan damarlarının gelişmesini tanımlar. Bu olay fizyolojik koşullarda oldukça önemlidir. Yara iyileşmesi, fertilizasyondan sonra plasenta gelişmesi, menstruasyondan sonra uterus iç tabakasınınyenilenmesindeanjiogenezyer alır. Proanjiogenik ve anti anjiogenik faktörler arasındakidengebozulduğundaanjiogenez kontrol edilemez. Bu olay özellikle tümörlerin yayılmasında önemli olabilir. Bu derleme yazısında anjiogenezin temel moleküler mekanizmalarını ve tümör anjiyogenezini gözden geçirdik.

Molecular basis of angiogenesis mechanisms and tumor angiogenesis

Background and Design.- Angiogenesis is a term that describes the formation of new capillaries from a preexisting vasculature. This process is very important in physiologic conditions. It helps healing injured tissues, and in female population it helps forming the placenta after fertilization and reconstructs the inside layer of the uterus after menstruation. When the balance between proangiogenic and antiangiogenic factors is disturbed, angiogenesis is not controlled. This status may be important in tumor metastasis. In the review, we considered the molecular basis of angiogenesis and tumor angiogenesis.

PDF

___

1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653- 660.
2. Issa R, Krupinski J, Bujny T, Kumar S, Kaluza J, Kumar P. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke. Lab Invest. 1999; 9: 417-425.
3. Slevin M, West D, Kumar P, Rooney P, Kumar S. Hyaluronan, angiogenesis and malignant disease. Int J Cancer. 2004; 109: 793- 794.
4. Luttun A, Dewerchin M, Collen D, Carmeliet P. The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies. Curr Atheroscler Rep. 2000; 2: 407- 416.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3: 401- 410.
6. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 2000; 21: 505- 515.
7. Yin G, Liu W, An P, Li P, Ding I, Planelles V, Schwarz EM, Min W. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther. 2002; 5: 547- 554.
8. Folkman Y, Shing Y. Angiogenesis. J Biol Chem. 1992; 267: 10931–10934.
9. Folkman J. Angiogenesis and angiogenesis inhibition: An overview. EXS Regul Angiogenesis. 1997; 79: 1–7.
10. Intaglietta M, Johnson PC, Winslow RM. Microvascular and tissue oxygen distrubution. Cardiovasc Res. 1996; 32: 632–643.
11. Lawrence WT, Diegelmann RF. Growth factors in wound healing. Clin Dermatol. 1994; 12: 157- 169.
12. Goodsell DS. The moleculer perspective: VEGF and angiogenesis. Stem Cells. 2003; 21: 118–119.
13. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer .1996; 32A: 2423–2429.
14. Hu DE, Hori Y, Fan TP. İnterleukin–8 stimulates angiogenesis in rats. Inflammation. 1993; 17: 135- 143.
15. Cleaver O, Melton DA. Endothelial signalling during development. Nat Med. 2003; 9: 661- 668.
16. Allure R. Basement membranes: Structure, assembly and role in tumor angiogenesis. Nat Rev Cancer. 2003; 3: 422- 433.
17. Haroon ZA, Peters KG, Greenberg CS, Dewhirst MW. Angiogenesis and Oxygen Transport in Solid Tumors. In: Totowa, New Jersey, Teicher BA (eds). Antiangiogenic Agents in Cancer Therapy. 3- 21, Humana Press, 1999.
18. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 1996; 49: 117- 137.
19. Ausprunk DH and Folkman J. Migration and proiferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977; 14: 53–65.
20. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: Int J Cancer. 1997; 72: 1-22.
21. Blasi F. uPA, uPAR, PAI- 1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today.1997; 18: 415- 417.
22. Stepanova VV, Tkachuk VA. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc). 2002; 67: 109- 118.
23. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669- 676.
24. Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996; 49: 138–162.
25. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995; 15: 4738- 4747.
26. Zachary I, Mathur A, Yla-Herttuala S, Martin J. Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2000; 20: 1512- 1520.
27. Servos S, Zachary I, Martin JF. VEGF modulates NO production: The basis of a cytoprotective effect? Cardiovasc Res. 1999; 41: 509-510.
28. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor- 1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991; 181: 902- 906.
29. Turhan MS. Meme tümörlü hastalarda vaskuler endotelyal büyüme faktörü, nitrik oksit ve ürokinaz plazminojen aktivator. İÜ Cerrahpaşa Tip Fakültesi Tıpta Uzmanlık tezi, 2004.
30. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59: 21- 6.
31. Steiling H, Werner S. Fibroblast growth factors: Key players in epithelial morphogenesis, repair and cytoprotection. Curr Opin Biotechnol. 2003; 14: 533-537.
32. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res Part C Embryo Today. 2003; 69: 272- 285.
33. Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol Ther. 2003; 98: 257- 265
34. Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. J Nucl Med. 2003; 47: 149- 161.
35. Ide AG, Bake NH, Warren SL. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol. 1939; 42: 891–899.
36. Algire GH, Chalkey HW, Legallais FY, Park H. Vascular reactions of normal and malignant tumours in vivo. JNCI. 1945; 6: 73–85.
37. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med. 1971; 285: 1182-1186.
38. Chodak GW, Haudenschild C, Gittes FF, Folkman J. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg. 1980; 192: 762-771.
39. McNamara DA, Harmey JH, Walsh TN, Redmond HP, Bouchier-Hayes DJ. Significance of angiogenesis in cancer therapy. Br J Surg. 1998; 85: 1044-1055. İstanbul Üniv. Cerrahpaşa Tıp Fak. Temel Bilimleri
40. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol. 2002; 9: 401-406.
41. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene. 2003; 22: 6549-6556.
42. Nicolson GL. Organ specificity of tumor metastasis: Role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988; 7: 143 -188.
43. Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA, Sweep CG. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer. 2002; 87: 772 -778.
44. Rosen LS. Clinical experience with angiogenesis signalling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002; 9: 36-44.
45. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol. 2000; 18: 1423 -1431.
46. Carter SK. Clinical strategy for the development of angiogenesis inhibitors. Oncologist. 2000; 5.51–54
47. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992; 52: 6702–6704.